Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity.

Garrido G, Schrand B, Rabasa A, Levay A, D'Eramo F, Berezhnoy A, Modi S, Gefen T, Marijt K, Doorduijn E, Dudeja V, van Hall T, Gilboa E.

Nat Commun. 2019 Aug 21;10(1):3773. doi: 10.1038/s41467-019-11728-2.

2.

Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.

Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger AB.

J Clin Invest. 2019 Jan 2;129(1):137-149. doi: 10.1172/JCI121266. Epub 2018 Nov 19.

3.

Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.

Schrand B, Clark E, Levay A, Capote AR, Martinez O, Brenneman R, Castro I, Gilboa E.

Nat Commun. 2018 Aug 22;9(1):3348. doi: 10.1038/s41467-018-05566-x.

4.

Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition.

Puplampu-Dove Y, Gefen T, Rajagopalan A, Muheramagic D, Schrand B, Gilboa E.

Oncoimmunology. 2018 Feb 15;7(4):e1349588. doi: 10.1080/2162402X.2017.1349588. eCollection 2018.

5.

Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.

Rajagopalan A, Berezhnoy A, Schrand B, Puplampu-Dove Y, Gilboa E.

Mol Ther. 2017 Jan 4;25(1):54-61. doi: 10.1016/j.ymthe.2016.10.021. Epub 2017 Jan 4.

6.

Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation.

Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, Ishkanian A.

Cancer Res. 2017 Mar 15;77(6):1310-1321. doi: 10.1158/0008-5472.CAN-16-2105. Epub 2017 Jan 12.

7.

4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models.

Benaduce AP, Brenneman R, Schrand B, Pollack A, Gilboa E, Ishkanian A.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):458-461. doi: 10.1016/j.ijrobp.2016.05.013. Epub 2016 May 21.

PMID:
27598810
8.

Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB.

Oncoimmunology. 2015 Dec 21;5(5):e1117739. doi: 10.1080/2162402X.2015.1117739. eCollection 2016 May.

9.

Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.

Gilboa E, Berezhnoy A, Schrand B.

Cancer Immunol Res. 2015 Nov;3(11):1195-200. doi: 10.1158/2326-6066.CIR-15-0194. Review.

10.

Reducing toxicity of 4-1BB costimulation: targeting 4-1BB ligands to the tumor stroma with bi-specific aptamer conjugates.

Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Gilboa E.

Oncoimmunology. 2015 Jan 9;4(3):e970918. eCollection 2015 Mar.

11.

CORRIGENDUM: Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells.

Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, Ao Z, Brenneman R, Gilboa E, Lu B, Wang S, Zhu J, Datar R, Cote R, Tai YC, Zheng SY.

Sci Rep. 2015 Jan 27;5:7967. doi: 10.1038/srep07967. No abstract available.

12.

Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells.

Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, Ao Z, Brenneman R, Gilboa E, Lu B, Wang S, Zhu J, Datar R, Cote R, Tai YC, Zheng SY.

Sci Rep. 2014 Dec 9;4:7392. doi: 10.1038/srep07392. Erratum in: Sci Rep. 2015;5:7967.

13.

Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.

Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E.

Cancer Immunol Res. 2014 Sep;2(9):867-77. doi: 10.1158/2326-6066.CIR-14-0007. Epub 2014 Jun 17.

Supplemental Content

Loading ...
Support Center